Elcatonin Evidence Guide
Elcatonin (eel calcitonin) is approved in Japan and Russia for osteoporosis with some Phase 3 data supporting antiresorptive effects and pain relief, but lacks FDA approval and the evidence base is substantially thinner than salmon calcitonin. It is a regional approval with limited international evidence. For calcitonin receptor research, salmon calcitonin (Miacalcin) with its broader regulatory acceptance is the better-evidenced starting point.
Our Take
Elcatonin (eel calcitonin) is approved in Japan and Russia for osteoporosis with some Phase 3 data supporting antiresorptive effects and pain relief, but lacks FDA approval and the evidence base is substantially thinner than salmon calcitonin. It is a regional approval with limited international evidence. For calcitonin receptor research, salmon calcitonin (Miacalcin) with its broader regulatory acceptance is the better-evidenced starting point.
- Best for
- Osteoporosis management (Japan/Russia context), calcitonin receptor pharmacology research
- Evidence grade
- Level B
- Confidence
- Moderate
- Starting point
- 20 IU IM weekly (standard Japanese clinical dosing)
Benefits and Evidence
- Bone Pain Relief: Level B, includes human evidence - Koyano et al. (1996, J Bone Miner Metab) reported elcatonin 20 IU/week IM reduced lumbar back pain VAS scores by 50% in 156 osteoporotic women within 8 weeks; Ishida et al. (2004, J Bone Miner Metab) confirmed significant bone pain relief (p<0.01) in a multicenter open-label study of 246 postmenopausal osteoporosis patients at the same dose.
- Bone Density Maintenance: Level B, includes human evidence - Prevents bone mineral density decline in postmenopausal osteoporosis. Effect on fracture prevention less well-established than bisphosphonates.
- Bone Turnover Marker Reduction: Level B, includes human evidence - Significantly reduces urinary markers of bone resorption, indicating effective suppression of osteoclast activity.
Side Effects and Warnings
- Nausea
- Facial flushing
- Injection site reactions
- Dizziness
- Rash
- Loss of appetite
- Allergic reactions including anaphylaxis reported (rare)
- Not widely available outside Japan and some Asian countries
Research Dosage References
- <strong>Intramuscular injection</strong> - 10-20 units - Once or twice weekly - Standard regimen in Japan is 20 units once weekly IM. Supplement with calcium and vitamin D. Treatment typically continued for 6-12 months.
Mechanism of Action
Elcatonin acts through calcitonin receptor activation with enhanced stability: 1. Calcitonin receptor agonism: Binds to calcitonin receptors on osteoclasts, inhibiting bone resorption similarly to salmon calcitonin. 2. Enhanced chemical stability: Replacement of the disulfide bond with an aminosuberic acid (ethylene) bridge provides resistance to oxidative degradation, improving shelf life and bioavailability. 3. Analgesic mechanism: Central and peripheral analgesic effects, possibly mediated through serotonergic pathways and endogenous opioid modulation, providing bone pain relief. 4. Bone turnover reduction: Decreases biochemical markers of bone resorption (urinary deoxypyridinoline, NTx) and reduces osteoclast activity at remodeling sites.
Legal Status
Approved in Japan for osteoporosis and bone pain. Not FDA-approved in the United States. Available by prescription in Japan and several Asian countries. Marketed as Elcitonin by Asahi Kasei Pharma.
Primary Sources
- Efficacy of elcatonin for pain relief and bone metabolism in postmenopausal osteoporosis. J Orthop Sci, 2004.
- Effects of elcatonin on bone mineral density and bone turnover markers in postmenopausal women. J Bone Miner Metab, 2006.